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Abstract
Background : Bronchial asthma is a chronic inflammatory and remodeling disorder of the airways, in which many
cells, cellular elements, and cytokines play important roles. Stem cell factor (SCF) may contribute to the inflammatory
changes occurring in asthma. We aimed to show the expression of SCF gene in patients with asthma as a means of
diagnosis and its association with severity and atopic state in these patients.
Methods: This study was carried out on 80 subjects, 50 asthmatic patients and 30 age and gender matched
healthy control persons. They were subjected to full history taking, general and local chest examination,
spirometric measurements (pre and post broncodilators) using a spirometer, serum IgE, and real time PCR for
assessment of SCF mRNA expression.
Results: This study showed significant difference between the studied groups regarding pulmonary function
tests (P < 0.001). Asthmatic patients had significant higher SCF expression compared to control (P < 0.001), also
atopic patients vs non atopic (P = 0.03) and severe asthmatic patients vs mild ones (P < 0.001). SCF expression
at cut off point (0.528) is sufficient to discriminate asthmatic patients from control while at cut off point (1.84) for
discrimination of atopic patients from non-atopic patients and at cut off point (1.395) for discrimination of severe
asthmatic patients from mild ones. A significant negative correlation between SCF expression and inhaled steroid while
significant positive correlation with serum IgE was found.
Conclusion: Measuring SCF mRNA expression can be used as an efficient marker for evaluation of atopy and detection
of severity of bronchial asthma.
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Background
Bronchial asthma is a chronic inflammatory and remodel-
ing disorder of the airways, in which many cells, cellular
elements, and cytokines play important roles. Many
cytokines released by T cells, innate, and structural
cells contribute to the different pathogenetic features
of asthma [1]. Bronchial asthma is defined by the his-
tory of respiratory symptoms such as wheeze, short-
ness of breath, chest tightness and cough that vary
over time and in intensity, together with variable ex-
piratory airflow limitation [2]. Previously published
evidence suggested that both environmental components
and genetic variations may contribute to asthma suscepti-
bility [3]. The major mast cell growth factor, stem cell fac-
tor (SCF) is a cytokine that may contribute to the
inflammatory changes occurring in diseases associated
with an increased mast cell number and activation, like
asthma [4]. The gene for SCF in humans is located on
chromosome 12q22-q24 and SCF protein is expressed in
two forms soluble form (sSCF) and membrane-bound
form (mSCF) [5].
The sSCF and mSCF isoforms are formed by alternative
splicing and both are biologically active. SCF248 includes
exon 6, which encodes a proteolytic cleavage site, resulting
in the production of soluble SCF. The lack of exon 6 in
human SCF220 produces the transmembrane form of
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human SCF. The ratio of SCF248 mRNA to SCF220 mRNA
varies considerably in different tissues, ranging from 10:1
in the brain and 4:1 in the bone marrow to 0.4:1 in
the testis [6].
SCF is expressed in vitro by various cells from the air-
ways, including the bronchial epithelial cells, lung
fibroblasts, bronchial smooth muscle cells, endothelial
cells, peripheral blood eosinophils and mast cells. Once
released, SCF acts on all cells that express the Kit
receptor [4]. Human mast cells produce more mSCF
than sSCF [7] while pulmonary fibroblasts and smooth
muscle cells produce more sSCF than mSCF [8].
SCF initiates its effects by binding to the c-kit recep-
tor, which results in receptor dimerization and activation
of multiple signaling pathways; including the Erk1/2
and p38 mitogen-activated protein kinase (MAPK)
pathways [9].
The Kit receptor is expressed on cells that respond to
SCF, including the haematopoietic progenitor cells and
lymphoid lines, melanocytes, germinal cells, eosinophils
in the peripheral blood, basophils and mast cells [4].
Signaling from c-Kit is crucial for normal hematopoiesis,
pigmentation, fertility, gut movement, and some aspects
of the nervous system. Deregulated c-Kit kinase activity
has been found in a number of pathological conditions,
including cancer and allergy [10]. The stimulation of mast
cells by SCF can induce their adhesion to extracellular
matrix and degranulation, leading to the production and
release of histamine, pro-inflammatory cytokines and
chemokines. SCF also induces eosinophil adhesion and
activation [11].
SCF acts as an important growth factor for human and
murine mast cells [12], including in vitro proliferation
and differentiation of immature CD34+ mast cells in the
bone marrow [13], and CD34+ progenitors in peripheral
blood [14].
We aimed in this study to show the expression of
SCF gene in patients with asthma and its association
with severity and atopic state in these patients.
Methods
This case control study was carried out on 80 subjects,
50 asthmatic patients that were admitted in Chest De-
partment, Menoufia University Hospital and 30 age and
gender matched healthy control persons. All laboratory
investigations and genetic analysis were performed in
Medical Biochemistry Department, Faculty of Medicine,
Menoufia University. All subjects enrolled in the study
(patients and control) were nonsmoker. They were
divided into two groups:
Group 1: included 50 patients with persistent asthma
(24 (48%) males and 26 (52%) females). Their mean age
was 33.84 ± 1.46 year. Bronchial asthma was diagnosed
clinically based on symptoms and signs plus evidence of
expiratory airflow limitation (FEV1/FVC less than 0.7)
with positive reversibility test and variability. They were
classified into atopic (allergic) 23 (46%) and non-atopic
27 (54%) groups based on the family history, presence of
other atopic diseases like allergic rhinitis and dermatitis
and by measuring the level of serum IgE by ELISA [1].
Bronchodilator (BD) reversibility test was considered
positive if there was an increase in FEV1 of >12% and
>200 mL from baseline, 10–15 min after 200 mcg salbu-
tamol inhalation. All patients were on inhaled corticoste-
roids (budesonide) in a dose varying from 500 to
2000 mg/day according to severity, patients only receive
systemic corticosteroid during exacerbations. Patients
known to have systemic inflammatory diseases were
excluded from this study.
Severity of bronchial asthma in patients was assessed
based on the spirometric staging according to the Global
Initiative for Asthma (GINA) guidelines 2016 [2] and
the National Asthma Education and Prevention Program
(NAEPP) classification [15] (Mild: post BD FEV1 ˃ 80%
of predicted, Moderate: post BD 60–80% of predicted and
severe: post BD ˂ 60% of predicted), patients were classi-
fied into mild 16(32%), moderate 20(70%) and severe
14(28%) groups.
Group 2: included 30 apparently healthy subjects
served as a control group (13 (43.3%) males and 17
(56.7%) females). Their mean age was 35.23 ± 1.83 years.
All patients and control groups were subjected to the
following: full history taking, General examination, local
chest examination, spirometric measurements (pre and
post broncodilators) using a spirometer (Spiroanalyzer
ST-90 supplied by Fukuda Sangyo, Tokyo, Japan) and
Real time PCR for assessment of SCF mRNA expression.
Sample collection and assay: 2 ml of fresh venous
blood was collected from all subjects into EDTA con-
taining tube for estimation of SCF expression by Real
time PCR. Quantitative assay of SCF mRNA expression
in whole blood using reverse transcriptase polymerase
chain reaction (RT-PCR) technique was done as follow:
Sample preparation was done at first, then total RNA
isolation from whole blood using (Thermo Scientific
King Fisher Pure RNA extraction Kit, from Lithuania),
followed by assuring RNA quality and purity [16]. Ex-
tracted RNA was stored in -80 °C till time of use. First
step- PCR was cDNA synthesis (reverse transcription
step) using (MyTaq Tm one step RT PCR kit from
USA), using Applied Bio systems 2720 thermal cycler
(Singapore). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) primers were used in RT PCR reaction as
RNA loading control. Second step- PCR, was cDNA ampli-
fication (real time PCR step) (Fig. 1): The cDNA was used
in SYBR green based quantitative real-time PCR for quan-
tification of SCF gene expression by (SensiFAST TM SYBR
Lo-ROX Kit from USA), using the following designed
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primers (Midland,Texas). The primers were designed with
Oligo Primer Analysis software (Primers detect SCF
mRNA that produces both protein isoforms soluble and
membrane bound forms of SCF) and the sequences were
revised using primer blast (http://www.ncbi.nlm.nih.gov/
BLAST/).1-SCF primer sequence:
Forward primer 5′GAGCTCCAGAACAGCTAAACG-
3′, Reverse primer 5′- CACTCCACAAGGTCATCCAC
-3′ and 2- GAPDH primer sequence: Forward primer 5′
TGATGACATCAAGAAGGTGGTGAAG- 3′, Reverse
primer 5′ TCCTTGGAGGCCA TGTGGGC CAT-3′.
Data analysis with Applied Biosystems 7500 software
version 2.0.1. The relative quantification (RQ) of gene
expression performed using comparative ΔΔCt method
[17] where the amount of the target (SCF) mRNA, is
normalized to an endogenous reference gene (GAPDH)
and relative to a control. Each run was completed using
melting curve analysis to confirm specificity of the amp-
lification and absence of primer dimers.
Results
Results of this study showed that age and gender were
matched between studied groups (Table 1). The study also
showed high statistical significant difference between stud-
ied groups regarding pulmonary function tests (P < 0.001)
(Table 1). Serum IgE was significantly higher in atopic
patients versus non atopic ones (P < 0.001) (Table 2).
Asthmatic patients had significant higher SCF mRNA ex-
pression compared to control (P < 0.001), also atopic pa-
tients compared with non-atopic patients (P = 0.03) and
severe asthmatic patients compared with mild asthmatic
ones (P < 0.001) while SCF mRNA expression was not sig-
nificant between males and female patients (P < 0.05)
(Table 3). SCF mRNA expression at cut off point (0.528) is
sufficient to discriminate asthmatic patients from control
that gives a sensitivity of 92% and a specificity of 84.6%
(Table 4, Fig. 2a) while at cut off point (1.84) for discrim-
ination of atopic patients from non-atopic patients with
sensitivity of 80% and a specificity of 81.2% (Table 4,
Fig. 2b). Furthermore, SCF mRNA expression at cut off
point (1.395) can discriminate severe asthmatics from
mild asthmatics with sensitivity of 96% and a specificity of
80% (Table 4, Fig. 2c). Moreover, results showed negative
correlation between SCF mRNA and pulmonary function
tests FEV1/FVC % and FEV1% predicted in asthmatic
group (r = -0.436 and -0.559) respectively, p-value for both
(<0.001) (Fig. 2d& e) while significant positive correlation
between SCF expression and serum IgE levels (Ku/ml) in
asthmatic patients, (r = 0.448 and p-value <0.001) (Fig. 2f).
SCF expression was negatively correlated with inhaled
Fig. 1 Amplification plot of SCF mRNA gene expression (normalized fluorescence signal (ΔRn) plotted versus cycle number). The plate of real
time instrument divided into 96 wells, arranged in 12 columns and 8 rows, the legend represents colors of fluorescence emitted from each 12
samples of 8 rows (from A to H)
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budesonide dose (mg/day) in asthmatic patients, (r = -
0.282 and p-value <0.047) (Fig. 2g).
Statistical analysis
Results were collected, tabulated and statistically ana-
lyzed by IBM personal computer and statistical package
SPSS version 20. Student t-test used for comparison
between two groups having quantitative variables. Chi-
square test (χ2): was used to study association between
two qualitative variables. Mann whitney and Kruskal –
Wallis tests for comparison two and three groups of not
normally distributed variables respectively. P-value < 0.05
was considered statistically significant.
Discussion
Asthma is a highly prevalent disease involving a complex
interplay of environmental factors, airflow obstruction,
bronchial hyper-responsiveness, and inflammation. The
dominant feature that leads to clinical symptoms is
smooth muscle contraction and inflammation, which
results in narrowing of the airway and obstruction [18].
Numerous triggers can induce bronchoconstriction, such
as allergic responses, respiratory infections, exercise, irri-
tants, and non-steroidal anti-inflammatory drugs [19].
Mast cells and eosinophils are key cells in the inflamma-
tory process ongoing in the airways of patients with
asthma [20]. SCF also induces eosinophil adhesion and
activation [11].
The present study revealed that pulmonary function
tests (FEV1/FVC % & FEV1% predicted) were signifi-
cantly decreased in asthmatic group when compared to
the control group this comes in line with [20] and [21].
In the current study, there was a significant statistical
increase of SCF mRNA expression in asthmatic group
when compared to controls, Furthermore, this expression
is significantly increased in atopic than non-atopic
patients. Our observations are in line with Al-Muhsen et
al. [22] who reported that, the expression of mRNA for
SCF and its receptor c-kit were shown to be higher in the
bronchi of patients with asthma as compared to controls.
Da Silva and Frossard, [4] also concluded that, SCF
expression increases in the airways of asthmatic patients,
and this is reversed after treatment with glucocorticoids.
SCF may be proposed as an interesting target for asthma
treatment through its effect on the regulation of the num-
ber and activation status of mast cells. Also, Lei et al., [21]
Suggested that allergic asthma is characterized by an ele-
vation of cytokines SCF and IL-31 and the measurement
of their expression at either protein level in serum or
mRNA level in Peripheral Blood Mononuclear Cells
(PBMCs) will be a valuable parameter for the diagnosis of
allergic asthma. Makowska et al., [20] found that expres-
sion of mRNA for SCF is significantly increased in nasal
epithelia of patients with allergic rhinitis.
Kowalski et al., [23] demonstrated increased expres-
sion of SCF in cultured epithelial cells. Furthermore, ex-
pression of SCF in epithelial cells and the density of
mast cells in polyps tissue correlated with the number of
polypectomies, suggesting a patho- physiological link
between SCF, mast cells and severity of nasal polyposis.




t- test P value
Patients (n = 50) 257.14 ± 32.24 5.37 <0.001
Controls (n = 30) 32.37 ± 3.80
Atopic patients (n = 23) 452.88 ± 24.12 14.5 <0.001
Non atopic patients (n = 27) 45.08 ± 12.90
Table 1 Demographic, clinical data and pulmonary function tests of studied groups
Patients (n = 50) Control (n = 30) Test P-value
Age in years (Mean ± SEM) 33.84 ± 1.46 35.23 ± 1.83 0.59a 0.55
No % No %
Gender Male 24 48% 13 43.3% 0.16b 0.68
Female 26 52% 17 56.7%
FEV1/FVC %(Mean ± SEM) 61.40 ± 0.80 87.67 ± 0.52 23.52a <0.001
FEV1% predicted (Mean ± SEM) 70.44 ± 1.83 93.47 ± 0.61 9.52a <0.001
Atopy Atopic 23 46%
Non atopic 27 54%
Severity Mild 16 32%
Moderate 20 70%
Severe 14 28%
Data are presented as mean and standard error mean (SEM)
FVC forced vital capacity, FEV1 Predicted forced expiratory volume in first second
a t -test, b chi-square (X2) test
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A recent study made by Moaaz and his coworkers [24]
demonstrated that the levels of SCF mRNAs in atopic
asthmatic patients’ PBMCs were significantly higher
than those in controls and nonatopic asthmatics.
Since SCF is the principal growth factor for mast cells,
it might be expressed in human bronchi and regulated
in airway structural cells in pro- and anti-inflammatory
conditions. That is, increased SCF expression in the
bronchi of a patient with asthma would be associated
with increased number and activation of mast cells [25].
The PBMCs in asthmatic patients express a high level
of SCF mRNA, which might be induced by the allergens
or asthma-associated factors. The significance of a high
level of SCF might be interpreted by the effect of SCF
on mast cells such as chemoattracting progenitor mast
cells from bone marrow to blood, activating mast cells,
thus maintaining the process of asthma [21].
Both mast cells and eosinophils express SCF [26] and its
c-Kit receptor at the cell membrane [27]. Salib et al., [28]
didnot find the differences in the expression of SCF
mRNA between patients with and without allergic rhinitis.
This study revealed a significant direct statistical associ-
ation between SCF mRNA expression and severity of
asthma being higher in patients with severe asthma when
compared to patients with mild and moderate asthma with
significant negative correlation between SCF mRNA and
markers of asthma severity such as FEV1/FVC % and
FEV1% predicted in asthmatic group. These findings con-
firm results obtained by Trudeau et al., [29] who demon-
strated that, the expression of mRNA for SCF was shown to
be higher in both epithelial and luminal compartments of
asthmatics bronchi as compared to controls. There were in-
verse relationship of epithelial and luminal SCF in relation
to asthmas symptoms, which suggest that the loss (slough-
ing) of SCF expressing cells from the epithelia, confers the
greatest risk for severe and poorly controlled asthmas.
El-Gazzar et al., [30] demonstrated that the serum level
of SCF was higher in asthmatic patients especially among
eosinophilic phenotype than among healthy control sub-
jects. Also there was a significant association between
higher SCF and higher levels of asthma severity and blood
eosinophil%.
In the present study there was significant positive correl-
ation between SCF expression and serum IgE levels (Ku/ml)
in asthmatic patients. This is in accordance with Lei et al.,
[21] who found that, SCF directly correlate with severity of
allergic asthma and it may be useful indicator for allergic
asthma providing a new clue for the diagnostic study of al-
lergic asthma, and may be useful for the treatment.
Moaaz and his coworkers [24] revealed a strong correl-
ation between SCF, IL-31 and between both of them and
IgE in asthmatics. A direct correlation between SCF, IL-31
Table 4 Validity of SCF mRNA expression for discrimination of patients from control, atopic patients from non-atopic patients and









SCF mRNA expression at cut off point (0.528) for discrimination of patients
from control.
92% 84.6% 90.1% 86.2% 88.7%
SCF mRNA expression at cut off point (1.84) for discrimination of atopic
patients from non-atopic patients.
80.0% 81.2% 86.9% 70.5% 80%
SCF mRNA expression at cut off point (1.395) for discrimination of severe
asthmatic patients from mild asthmatic patients.
96% 80% 88.9% 92.3% 90%
Table 3 Comparison of SCF mRNA expression between studied groups
SCF mRNA expression (Mean ± SEM) Test P value
Patients (n = 50) 5.64 ± 1.24 3.35b 0.001
Controls (n = 30) 0.25 ± 0.027
Male patients (n = 24) 4.05 ± 1.46 0.54c 0.60
Female patients (n = 26) 3.14 ± 0.9
Atopic patients (n = 23) 8.28 ± 2.44 2.12b 0.03
Non atopic patients (n = 27) 3.19 ± 0.49
Mild (n = 16) 0.81 ± 0.43 23.19a <0.001
Moderate (n = 20) 3.47 ± 1.45
Severe (n = 14) 10.25 ± 2.65
aKruskal-Wallis test, b t-test, c Mann- Whitney U test
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Fig. 2 (See legend on next page.)
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and FEV-1/ FVC %, CRP and wheezing existed and sug-
gested that both SCF and IL-31 play an important role in
mediating inflammation and enhancing severity of atopic
asthma.
Results of this study revealed a significant negative
correlation between SCF expression and the inhaled bude-
sonide dose (mg/day) in asthmatic patients. This in agree-
ment with Da Silva et al., [31], Da Silva and Frossard, [4]
and Makowska et al., [20] who reported that, the higher
expression of SCF in asthmatic bronchi in comparison to
healthy controls could be normalized by treatment with
inhaled glucocorticosteroids. Glucocorticoids may de-
crease mast cell number and activation through decreased
SCF expression.
Neutralizing SCF with a monoclonal antibody
administered by inhalation during antigen provocation
inhibits mast cell activation, bronchial inflammation
(as shown by the diminution of eosinophil infiltration)
[32], and bronchial hyperresponsiveness [33]. Consist-
ent with this finding, intra nasal administration of SCF
antisense oligonucleotides decreases lung SCF protein ex-
pression in a murine model of asthma, as well as airway
hyperresponsiveness, IL-4 production and eosinophil
number in the bronchoalveolar lavage [34].
Stem cell factor is a critical factor for hematopoiesis
and hematopoietic stem cell survival. It also has a role in
mobilization of bone marrow stem cells, as well as in
cell differentiation. SCF in conjunction with interleukin-
31 may play a significant role in airway remodeling by
promoting the recruitment of bone marrow-derived
fibroblast precursors in to the lung with the capacity to
promote lung myofibroblast differentiation [35].
The results of a recent in vitro assay showed that adult
T-cell leukemia stem cells (ATLSCs) cultured with cyto-
kines known to promote stem cell expansion, such as SCF,
showed highly proliferative activity and maintained their
stem cell fraction. Inhibition of c-kit–SCF signaling with
the neutralizing antibody ACK2 affected ATLSC self-
renewal and proliferation [36]. Also Kim and his
coworkers suggested that inhibition of SCF signaling using
cKit inhibitors such as masitinib might provide a novel
therapeutic opportunity for the prevention of diabetes-
induced retinal vascular leakage [37].
The need for further experiments to elucidate SCF
signaling in simple cell culture and use of cKit inhibitors
work would be of great value to clarify therapeutic
potential of SCF inhibitors in preventing airway inflam-
mation in bronchial asthma.
Conclusion
Measuring SCF mRNA expression can be used as an effi-
cient marker for differentiation of atopic asthmatic
patients from non atopic ones and also can be used for
detection of severity of bronchial asthma. Moreover, it can
be used for evaluation of response to inhaled budesonide
therapy in asthma.
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